Analyst Ratings for BioXcel Therapeutics (BTAI)
BTAI Rating Summary
BTAI Price Target Summary
- Highest: $10.00 (H.C. Wainwright)
- Lowest: $3.50 (UBS)
- Average: $5.92
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$5.92 (+126.7%)
* Over Last 12-Mos
Rating Score: 5 / 10
Percentile Rank: 53%
Avg. $ Target:
$5.92 (+126.7%)
* Over Last 12-Mos
Rating Score: 5 / 10
Percentile Rank: 53%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/21/2024 | UBS » Updated 3/13/2024 |
Colin Bristow | Downgrade | Neutral (Buy) |
3.50 (4.00) |
3.51 (2.61) |
-25.64% | Details |
| 10/4/2023 | Truist Securities | Robyn Karnauskas | Downgrade | Hold (Buy) |
N/A (N/A) |
2.34 (2.61) |
11.54% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
